SCHEMBL5642647

SCHEMBL5642647

C=CCOc1ccc(O[Si](c2ccccc2)(c2ccccc2)C(C)(C)C)cc1N1C(=O)c2ccccc2C1=O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.36
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ SCN2A Q99250 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ PDCD1 Q15116 1/20 0.33
▸ CD274 Q9NZQ7 1/20 0.33
▸ NR1H3 Q13133 3/20 0.33
▸ NR1H2 P55055 2/20 0.33
▸ MEN1 O00255 2/20 0.33
▸ KMT2A Q03164 2/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ GRM5 P41594 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6005484 0.81 SCN2A (0.53) ALDH1A1RAB9ASCN2ANR1H3NR1H2
SCHEMBL6005753 0.80 ALDH1A1 (0.46) ALDH1A1NPC1RAB9ASMN1; SMN2SCN2A
SCHEMBL5644517 0.79 TYMS (0.42) SCN2ARECQLPDCD1CD274NR1H3
SCHEMBL5642923 0.79 MEN1 (0.37) ALDH1A1NPC1RAB9ASMN1; SMN2MEN1
SCHEMBL6005958 0.73 ALDH1A1 (0.46) ALDH1A1NPC1RAB9ASMN1; SMN2RECQL
SCHEMBL7451753 0.69 NPC1 (0.49) ALDH1A1NPC1RAB9ASMN1; SMN2SCN2A
SCHEMBL6393571 0.68 MEN1 (0.40) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL22546608 0.65 CA12 (0.37) ALDH1A1RAB9ANPSR1GAATSHR
SCHEMBL9569532 0.64 ALDH1A1 (0.36) ALDH1A1SMN1; SMN2MEN1KMT2AHTT
SCHEMBL9781271 0.64 PPOX (0.58) ALDH1A1NPSR1GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7163939-B2 Macrocyclic kinase inhibitors ABBOTT LABORATORIES (US) 2007-01-16 — — US disclosed
EP-1682555-A1 MACROCYCLIC KINASE INHIBITORS ABBOTT LABORATORIES (US) 2006-07-26 — — EP disclosed
US-20050215556-A1 Macrocyclic kinase inhibitors ABBVIE INC. 2005-09-29 — — US disclosed
WO-2005047294-A1 MACROCYCLIC KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215556-A1 Macrocyclic kinase inhibitors MAP3K20, MAP3K19, MAP3K7 ALDH1A1 4408/4885NPC1 2395/4885RAB9A 2377/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback